References
- 1
Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S.
A common polymorphism in the 5′-untranslated region of the VEGF gene is associated
with diabetic retinopathy in type 2 diabetes.
Diabetes.
2002;
51
1635-1639
- 2
Bennet W M, Wang Z L, Jones P M, Wang R M, James R F, London N J, Ghatei M A, Bloom S R.
Presence of neuropeptide Y and its messenger ribonucleic acid in human islets: evidence
for a possible paracrine role.
J Clin Endocrinol Metab.
1996;
81
2117-2120
- 3
Birinci A, Birinci H, Abidinoglu R, Durupinar B, Oge I.
Diabetic retinopathy and HLA antigens in type 2 diabetes mellitus.
Eur J Ophthalmol.
2002;
12
89-93
- 4
Ding B.
Distribution of the NPY 1128C allele frequency in different populations.
J Neural Transm.
2003;
110
1199-1204
- 5
El-Asrar A M, Al-Rubeaan K A, Al-Amro S A, Moharram O A, Kangave D.
Retinopathy as a predictor of other diabetic complications.
Int Ophthalmol.
2001;
24
1-11
- 6
Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner S M, Stern M P.
Mode of onset of type 2 diabetes from normal or impaired glucose tolerance.
Diabetes.
2004;
53
160-165
- 7
Harris M I, Klein R, Welborn T A, Knuiman M W.
Onset of NIDDM occurs at least 4 - 7 yr before clinical diagnosis.
Diabetes Care.
1992;
15
815-819
- 8
Jaakkola U, Kuusela T, Jartti T, Pesonen U, Koulu M, Vahlberg T, Kallio J.
The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion,
delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine
during oral glucose-tolerance test.
J Clin Endocrinol Metab.
2005;
90
3646-3652
- 9
Kallio J, Pesonen U, Jaakkola U, Karvonen M K, Helenius H, Koulu M.
Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects
with Leu7Pro polymorphism in the prepro-neuropeptide Y.
J Clin Endocrinol Metab.
2003;
88
3278-3283
- 10
Kallio J, Pesonen U, Kaipio K, Karvonen M K, Jaakkola U, Heinonen O J, Uusitupa M I,
Koulu M.
Altered intracellular processing and release of neuropeptide Y due to leucine 7 to
proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.
FASEB J.
2001;
15
1242-1244
- 11
Kallio J, Pesonen U, Karvonen M K, Kojima M, Hosoda H, Kangawa K, Koulu M.
Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY.
J Clin Endocrinol Metab.
2001 b;
86
5348-5352
- 12
Karvonen M K, Valkonen V P, Lakka T A, Salonen R, Koulu M, Pesonen U, Tuomainen T P,
Kauhanen J, Nyyssonen K, Lakka H M, Uusitupa M I, Salonen J T.
Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the
progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish
men.
Atherosclerosis.
2001;
159
145-151
- 13
Karvonen M K, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker J M, Hart L M,
Valve R, Uusitupa M I.
Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide
Y with high serum cholesterol and LDL cholesterol levels.
Nat Med.
1998;
4
1434-1437
- 14
Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, Geng Y, Karvonen M K,
Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee E W, Higgins R D, Zukowska Z.
Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy
and retinal neovascularization.
Ann Med.
2004;
36
232-240
- 15
Kumaramanickavel G, Sripriya S, Vellanki R N, Upadyay N K, Badrinath S S, Arokiasamy T,
Sukumar B, Vidhya A, Joseph B, Sharma T, Gopal L.
Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India.
Diabetes Res Clin Pract.
2001;
54
89-94
- 16
Lee E W, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A,
Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant D S, Zukowska Z.
Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal
muscles.
J Clin Invest.
2003;
111
1853-1862
- 17
Neugebauer S, Baba T, Watanabe T.
Association of the nitric oxide synthase gene polymorphism with an increased risk
for progression to diabetic nephropathy in type 2 diabetes.
Diabetes.
2000;
49
500-503
- 18
Niskanen L, Karvonen M K, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J,
Laakso M, Uusitupa M I.
Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with
enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control
subjects.
J Clin Endocrinol Metab.
2000;
85
2266-2269
- 19
Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen M K, Valve R, Pesonen U,
Laakso M, Uusitupa M I, Koulu M.
Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with
retinopathy in type 2 diabetes.
Exp Clin Endocrinol Diabetes.
2000 b;
108
235-236
- 20
Nordman S, Ding B, Ostenson C G, Karvestedt L, Brismar K, Efendic S, Gu H F.
Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired
glucose tolerance and type 2 diabetes in Swedish men.
Exp Clin Endocrinol Diabetes.
2005;
113
282-287
- 21
Olmos P, Futers S, Acosta A M, Siegel S, Maiz A, Schiaffino R, Morales P, Diaz R,
Arriagada P, Claro J C, Vega R, Vollrath V, Velasco S, Emmerich M.
(AC)23 [Z‐2] polymorphism of the aldose reductase gene and fast progression of retinopathy
in Chilean type 2 diabetics.
Diabetes Res Clin Pract.
2000;
47
169-176
- 22
Pedrazzini T, Pralong F, Grouzmann E.
Neuropeptide Y: the universal soldier.
Cell Mol Life Sci.
2003;
60
350-377
- 23
Pettersson-Fernholm K, Karvonen M K, Kallio J, Forsblom C M, Koulu M, Pesonen U, Fagerudd J A,
Groop P H. FinnDiane Study Group .
Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with
proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients.
Diabetes Care.
2004;
27
503-509
- 24
Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U,
Kallio J, Uusitupa M, Laakso M.
The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism.
Metabolism.
2003;
52
643-646
- 25
Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P.
Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria
in diabetes.
Diabetes.
2004;
53
861-864
- 26
Rohner-Jeanrenaud F.
Neuroendocrine regulation of nutrient partitioning.
Ann N Y Acad Sci.
1999;
892
261-271
- 27
Satoh C, Satoh F, Takahashi K, Murakami O, Sone M, Totsune K, Yabe T, Ohneda M, Fukuda M,
Sugimura K, Ogawa S, Nagakubo H, Sato T, Mouri T.
Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary
excretion in patients with advanced diabetic nephropathy.
Endocr J.
1999;
46
139-146
- 28
Taverna M J, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Chevalier A, Slama G, Reach G,
Selam J L.
eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe
diabetic retinopathy.
Diabet Med.
2002;
19
240-245
MD Ulriikka Jaakkola
Department of Pharmacology, Drug Development and Therapeutics
University of Turku
Itäinen Pitkäkatu 4B
20520 Turku
Finland
Telefon: + 358-50-5462328
Fax: + 358-2-333 72 16
eMail: ulriikka.jaakkola@utu.fi
